Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance
- 1 October 1996
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 52 (7) , 979-990
- https://doi.org/10.1016/0006-2952(96)00301-2
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- DNA Topoisomerases: Essential Enzymes and Lethal TargetsAnnual Review of Pharmacology and Toxicology, 1994
- Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemiaBlood, 1994
- When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugsChemical Research in Toxicology, 1993
- Thymocyte apoptosis induced by p53-dependent and independent pathwaysNature, 1993
- Expression of topoisomerase II, catalase, metallothionein and thymidylate-synthase in human squamous cell lung carcinomas and their correlation with doxorubicin resistance and with patients' smoking habitsCarcinogenesis: Integrative Cancer Research, 1992
- Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1992
- Cell death induced by topoisomerase inhibitors: Role of calcium in mammalian cellsBiochemical Pharmacology, 1991
- Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line: Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferaseBiochemical Pharmacology, 1991
- DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGSAnnual Review of Biochemistry, 1989
- Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase IIScience, 1984